Avenue Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATXI research report →
Range $12 – $12
Price Chart
About the company
Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product candidate is intravenous Tramadol, a synthetic opioid with a dual mechanism of action, currently undergoing Phase III clinical trials for the management of severe pain experienced by patients after surgery.
- CEO
- Alexandra MacLean
- IPO
- 2017
- Employees
- 1
- HQ
- Bay Harbor Islands, FL, US
Get TickerSpark's AI analysis on ATXI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.25M
- P/E
- -0.45
- Fwd P/E
- 0.35
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 2.20
- EV/EBITDA
- 0.23
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -155.23%
- ROIC
- -579.44%
Latest fiscal year · YoY change
- Revenue
- $1.40M+0.0%
- Gross Profit
- $1.40M+0.0%
- Op Income
- $-3,286,000
- Net Income
- $-2,909,000+75.0%
- EPS
- $-0.93-3.3%
- OCF Growth
- +79.7%
- FCF Growth
- +79.7%
- 52W High
- $0.97
- 52W Low
- $0.15
- 50D MA
- $0.42
- 200D MA
- $0.37
- Beta
- -0.17
- RSI (14)
- 44
- Avg Volume
- 6.41K
No earnings-call transcripts are available for ATXI yet.
- Free Float
- 86.5%
- Shares Outstanding
- 3.29M
- Float Shares
- 2.85M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 2, 26 | Fortress Biotech, Inc. | other | 111,209 |
| Mar 31, 25 | Fortress Biotech, Inc. | other | 33,724 |
| Dec 31, 24 | Fortress Biotech, Inc. | other | 0 |
| Dec 2, 24 | Herskowitz Neil | sell | 23 |
| Nov 5, 24 | KRANZLER JAY D | sell | 61 |
| Sep 30, 24 | KRANZLER JAY D | buy | 497 |
| Sep 27, 24 | KRANZLER JAY D | buy | 3 |
| Sep 23, 24 | ROSENWALD LINDSAY A MD | other | 30,000 |
| Sep 23, 24 | Herskowitz Neil | other | 30,000 |
| Sep 23, 24 | Oltmans Curtis Gale | other | 30,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ATXI coverage
Recent articles, reports, and earnings notes.
No research on ATXI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ATXI report →Avenue Therapeutics (NASDAQ:ATXI) and Collegium Pharmaceutical (NASDAQ:COLL) Head-To-Head Survey
defenseworld.net · Aug 13
Comparing Avenue Therapeutics (NASDAQ:ATXI) & Graybug Vision (NASDAQ:GRAY)
defenseworld.net · Apr 25
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
globenewswire.com · Feb 23
Reviewing Avenue Therapeutics (NASDAQ:ATXI) and Endonovo Therapeutics (OTCMKTS:ENDVD)
defenseworld.net · Feb 19
Contrasting ObsEva (NASDAQ:OBSV) & Avenue Therapeutics (NASDAQ:ATXI)
defenseworld.net · Jan 10
NexImmune (NASDAQ:NEXI) versus Avenue Therapeutics (NASDAQ:ATXI) Head-To-Head Comparison
defenseworld.net · Dec 25
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
globenewswire.com · Nov 6
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
globenewswire.com · Nov 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.